To date, CNS disease and neuropsychiatric symptoms of systemic lupus erythematosus (NP-SLE) have been understudied compared to end-organ failure and peripheral pathology. In this review, we focus on a specific mouse model of lupus and the ways in which this model reflects some of the most common manifestations and potential mechanisms of human NP-SLE. The mouse MRL lymphoproliferation strain (a...

Two children with lupus erythematosus and myelopathy were studied. The first child developed the neonatal lupus erythematosus syndrome associated with transplacentally acquired anti-Ro/SSA antibodies. The cutaneous manifestations of neonatal lupus erythematosus disappeared but a residual myelopathy was confirmed at 16 months of age. The second child developed cutaneous lupus erythematosus at 3 ...

Epidemiology Systemic lupus erythematosus (SLE) is a systemic connective tissue disease with a broad range of clinical manifestations characterized by inflammatory and immune-mediated pathogenetic mechanisms. Since the first report of stupor and coma in the 19th century, several neuropsychiatric (NP) syndromes have been reported in SLE. The neurologic syndromes secondary to central, peripheral ...

A 28-year-old woman presenting with subacute onset of a tetraplegia is described who was shown to have active systemic lupus erythematosus in association with high circulating anticardiolipin binding and lupus anticoagulant activity. The patient later developed severe symptomatic systemic and pulmonary hypertension and required emergency resuscitation. This case provides further support for an ...

Systemic Lupus Erythematosus (SLE) is a disorder of the immune system with wide range symptoms. The involvement kidneys, lungs and central nervous (CNS) denotes more severe character worse prognosis. Several neurological psychiatric manifestations may be present, most common being convulsion, neuropathies acute confusional state, but chorea seen in less than 2% patients. Recent studies show tha...

We studied the efficacy of cyclophosphamide pulse therapy (CYP) for refractory rheumatic diseases except for lupus nephritis. Thirty-five patients were included in all, that is 9 patients with systemic lupus erythematosus (SLE), 10 with rheumatoid arthritis (RA), 7 with polymyositis/dermatomyositis (PM/DM), 2 with progressive systemic sclerosis (PSS), 2 with anti-phospholipid antibody syndrome ...